Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America

Xen­tria will li­cense its ex­per­i­men­tal pul­monary sar­coido­sis drug to Meitheal Phar­ma­ceu­ti­cals in a deal worth up to $680 mil­lion.

Meitheal spun out Xen­tria in 2020, ac­cord­ing to Crain’s Chica­go Busi­ness. 

The com­pa­nies, both of which are based in Chica­go, said Tues­day that they en­tered in­to an ex­clu­sive mul­ti-year li­cens­ing agree­ment to com­mer­cial­ize Xen­tria’s lead can­di­date, XTMAB-16, which is be­ing test­ed as a treat­ment for a rare lung dis­ease that com­mon­ly oc­curs in women and African Amer­i­can pa­tients. The mon­o­clon­al an­ti­body is set to en­ter a Phase II clin­i­cal tri­al lat­er this year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN